+

WO2004047725A2 - Composes de 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine utilises comme inhibiteurs de l'integrase du vih - Google Patents

Composes de 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine utilises comme inhibiteurs de l'integrase du vih Download PDF

Info

Publication number
WO2004047725A2
WO2004047725A2 PCT/US2003/028363 US0328363W WO2004047725A2 WO 2004047725 A2 WO2004047725 A2 WO 2004047725A2 US 0328363 W US0328363 W US 0328363W WO 2004047725 A2 WO2004047725 A2 WO 2004047725A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
rarb
haloalkyl
independently
substituents
Prior art date
Application number
PCT/US2003/028363
Other languages
English (en)
Other versions
WO2004047725A3 (fr
Inventor
John S. Wai
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Priority to US10/526,280 priority Critical patent/US7399763B2/en
Priority to JP2004555293A priority patent/JP2005538184A/ja
Priority to CA002498566A priority patent/CA2498566A1/fr
Priority to DE60322919T priority patent/DE60322919D1/de
Priority to EP03812013A priority patent/EP1539714B1/fr
Priority to AU2003302382A priority patent/AU2003302382B2/en
Publication of WO2004047725A2 publication Critical patent/WO2004047725A2/fr
Publication of WO2004047725A3 publication Critical patent/WO2004047725A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is directed to 8-hydroxy-l-oxo-tei ⁇ ahyckopyrrolopyrazine compounds and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of the HIN integrase enzyme.
  • the compounds of the present invention and their pharmaceutically acceptable salts are useful for preventing or treating infection by HIN and for treating, delaying the onset of, or preventing AIDS.
  • a retrovirus designated human immunodeficiency virus is the etiological agent of the complex disease that mcludes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system.
  • This virus was previously known as LAV, HTLN-ITI, or ARN.
  • a common feature of retrovirus replication is the insertion by virally-encoded integrase of proviral D ⁇ A into the host cell genome, a required step in HIN replication in human T- lymphoid and monocytoid cells.
  • Integration is believed to be mediated by integrase in three steps: assembly of a stable nucleoprotein complex with viral D ⁇ A sequences; cleavage of two nucleotides from the 3' termini of the linear proviral D ⁇ A; covalent joining of the recessed 3' OH termini of the proviral D ⁇ A at a staggered cut made at the host target site.
  • the fourth step in the process, repair synthesis of the resultant gap may be accomplished by cellul r enzymes.
  • ⁇ ucleoLide sequencing of HIN shows the presence of a pol gene in one open reading frame [Ratner et al., Nature 1985, 313: 277].
  • Amino acid sequence homology provides evidence that the pol sequence encodes reverse transcriptase, integrase and an HIN protease [Toh et al., EMBO J. 1985, 4: 1267; Power et al., Science 1986, 231: 1567; Pearl et al interfere Nature 1987, 329: 351]. All three enzymes have been shown to be essential for the replication of HIN.
  • antiviral compounds which act as inhibitors of HIN replication are effective agents in the treatment of AIDS and similar diseases, including reverse transcriptase inhibitors such as azido ⁇ ymtdiiie (AZT) and efavirenz and protease inhbitors such as indfnavir an nelfinavir.
  • the compounds of this invention are inhibitors of H N integrase and inhibitors of HIN replication.
  • the inhibition of integrase in vitro and of HIN replication in cells is a direct result of inliibiting the strand transfer reaction catalyzed by the recombinant integrase in vitro in HIN infected cells.
  • a particular advantage of the present invention is highly specific inhibition of HTV integrase and HIN replication.
  • US 5,294,620 discloses certain l,6-naphthvridin-2-one derivatives having a ⁇ giotensin II antagonist activity.
  • WO 02/30426 discloses another group of 8-hydroxy-l,6-naphmyridine-7-carboxaraides as HTV integrase inhibitors, wherein the carboxamido nitrogen is directly or indirectly attached to a heterocycle.
  • WO 02/055079 discloses still another group of 8-hydroxy-l,6-naphthyridine-7-carboxamides as HIN integrase inhibitors, wherein the carboxamido nitrogen is part of a heterocyclic ring system.
  • WO 02/036734 discloses certain aza- and polyaza-naphthalenyl ketones to be HIN integrase inhbitors.
  • the ketones include certain l-aryl-l-(poly)azanaphthylenyl methanones and H eterocyclyl-l-(poly)azanaph ylerryl methanones.
  • Quinoliny], ⁇ aphthyridinyl, and quinoxalinyl are disclosed as suitable (poly)aza ⁇ aphthalenyl groups in the ketones.
  • WO 03/35076 discloses certain 5,6-dihydroxypyrimidine- -carboxamides as HIN integrase inhibitors
  • WO 03/35077 discloses certain ⁇ -substituted 5-hydroxy-6-oxb-l,6- dihydropyrimidine-4-carboxamides as HIN integrase inhibitors.
  • the present invention is directed to novel 8-hydroxy-l-oxo- tetrahydropyrrolopyrazine compounds. These compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIN integrase, the prevention of infection by HIN, the treatment of infection by HIN and in the prevention, treatment, and delay in the onset of AIDS, either as compounds or their pharmaceutically acceptable salts, or as pharmaceutical composition ingredients, whether or not in combination with other HTN/AIDS antivirals, anti-infectives, i munornodulators, antibiotics or vaccines. More particularly, the present invention includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof:
  • Rl is -H, -Ci-6 alkyl, -C3-.6 cycloalkyl, or -C1-6 alkyl which is substituted with 1 or 2 substituents each of which is independently: (1) C3_8 cycloalkyl,
  • each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C ⁇ 6 alkyl, or -O-Ci-g alkyl;
  • (2) -O-Ci-6 alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-Ci-6 alkyl, -O-Ci- ⁇ 5 haloalkyl, -S(O) n Rc, -C( O)N(RaRb), -SO 2 N(RaRb), -N(Ra)C(--. ⁇ )Rb -N(R )C ⁇ 2 c , -N(Ra)S ⁇ 2R c ,
  • R2 is -H or -Cl-6 alkyl
  • R5 is -H or -Cl-6 alkyl
  • R ⁇ is:
  • Rv independently has the same definition as R ;
  • HetB is a 5- or 6-membered saturated or ono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C ⁇ _6 alkyl, -C ⁇ _6 haloalkyl, -O-Cl-6 alkyl, -0-C ⁇ _6 haloalkyl, or oxo; and
  • HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C ⁇ _6 alkyl, -Ci-6 haloalkyl, -O-Cl-6 alkyl, -O-Cj-6 haloalkyl, or oxo;
  • each R a and Rb is independently -H or -Cl-6 alkyl
  • each R is independently a -Cj .-6 alkyl
  • each n is independently an integer equal to 0, 1 or 2.
  • the present invention also includes pharmaceutical compositions containing a compound of the present invention and methods of preparing such pharmaceutical compositions.
  • the present invention further includes methods of treating AIDS, methods of delaying the onset of AIDS, methods of preventing AIDS, methods of preventing infection by HIN, and methods of treating infection by HIN.
  • Other embodiments - aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims.
  • the present invention includes the 8-hydroxy-l-oxo-tetrahydropyrrolo ⁇ yrazines of
  • a first embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Rl is -C1-4 alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently
  • An aspect of the first embodiment is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein
  • Rl is as defined in the first embodiment
  • R ⁇ is:
  • Ru is -H or -Ci-6 alkyl
  • Rv is -H, -Cl-6 alkyl, -C3-.6 cycloalkyl, or independently has the same definition as Rl above;
  • HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C ⁇ _6 alkyl, -C1..6 haloalkyl, -O-Ci-6 alkyl, -O-Ci-6 haloalkyl, or oxo; and
  • HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C ⁇ _6 alkyl, -Ci-6 haloalkyl, -O-C1-.6 alkyl, -O-C1.6 haloalkyl, or oxo;
  • RV having "the same definition as Rl above” means that Rl in the definition of Rv is as defined in the instant embodiment, here the first embodiment, instead of as originally defined.
  • a second embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Rl is -(CH2) ⁇ -4-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently
  • An aspect of the second embodiment is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Rl is as defined in the second embodiment, R 6 is as defined in the foregoing aspect of the first embodiment except that Rl in the definition of R is as defined in the second embodiment; and all other variables are as originally defined.
  • a third embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Rl is
  • Rl is 4-fluorobenzyl.
  • Another aspect of the third embodiment is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Rl is as defined in the third embodiment, R6 is as defined in the foregoing aspect of the first embodiment except that Rl in the definition of Rv is as defined in the third embodiment; and all other variables are as originally defined.
  • Rl is 4-fluorobenzyl.
  • a fourth embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R is is -H or -C 1-4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments or aspects.
  • R 2 is -H.
  • a fifth embodiment of the present invention is a compound of Formula (J), or a pharmaceutically acceptable salt thereof, wherem R3 is -H or -Ci-4 alkyl; and all other variables are as originally defined or as defined in any of the preceding embodiments or aspects thereof.
  • R3 is -H.
  • An eighth embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Rk is;
  • HetA is a 5- or 6-membered heteroaromatic ring containing a Lotal of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2
  • HetA is optionally substituted with from 1 to 3 substituents each of which is independently -C1-.4 alkyl, -Cl-4 haloalkyl, -O-C1-4 alkyl, -O-Ci-4 haloalkyl, or oxo; or (iii) a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heteroaromatic ring is optionally substituted with from optionally substituted with from 1 to 3 substituents each of which is independently -Ci-6 alky], -Cl-6 haloalkyl, -O-Cl-6 alkyl, -O-Ci-6 haloalkyl, or oxo;
  • HetA is a 5- or 6-membered heteroaromatic ring containing 1 or 2 N atoms, wherein HetA is optionally substituted with from 1 to 3 substituents each of which is independently -Cl-4 alkyl, -Cl-4 haloalkyl, -O-C1-4 alkyl, -O-C ⁇ _4 haloalkyl, or oxo.
  • HetA is pyrrolyl, pyrazolyl, imidazolyl, pyridyl, or pyrazinyl; which is optionally substituted with from 1 to 3 substituents each of which is independently -Cl-4 alkyl (e.g., methyl), -Ci-4 haloalkyl (e.g., trifluoromethyl) , -O-CI-.4 alkyl (e.g., methoxy), -O-C1-4 haloalkyl (e.g., -OCF3), or oxo.
  • substituents each of which is independently -Cl-4 alkyl (e.g., methyl), -Ci-4 haloalkyl (e.g., trifluoromethyl) , -O-CI-.4 alkyl (e.g., methoxy), -O-C1-4 haloalkyl (e.g., -OCF3), or oxo.
  • a ninth embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Rk is:
  • phenyl which is optionally substituted with from 1 to 3 substituents each of which is independently -Cl-4 alkyl, -C1-4 alkyl-OH, -Cl-4 alkyl-Q-Ci- 4 alkyl, -C1.
  • a saturated heterocyclic ring selected from the group consisting of piperidinyl, morpholinyl, thiomorpholinyl, tbiazolidinyl, isothiazolidinyl, oxazolidinyl, isooxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, t'hiazinanyl, thia2epanyl, thiadiazepanyl, dithiazepanyl, azepanyl, diazepanyl, thiadiazinanyl, and dioxanyl; wherein the saturated heterocyclic ring is: (a) optionally substituted with from 1 to 4 substituents each of which is independently halogen, -Cl- alkyl, -Cl-4 haloal
  • HetA is a heteroaromatic ring selected from the group consisting of pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl; wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C1-4 alkyl, "C1-4 haloalkyl, -O-Ci-4 alkyl, -O-Ci- 4 haloalkyl, or oxo;
  • a tenth embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R5 j$ -H; and all other variables are as originally defined or as defined in any of the preceding embodiments or aspects thereof.
  • An eleventh embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein 6 is:
  • R u is -H or -Ci-4 alkyl
  • Rv is -I-I, -C1 alkyl, or cyclopropyl
  • HetB is a 5- or 6-membered saturated ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the saturated ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C1.4 alkyl, -Ci-4 haloalkyl, -O-C14 alkyl, -O-C ⁇ 4 haloalkyl, or oxo; and
  • HetC is a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C14 alkyl, -C1.4 haloalkyl, -O-Ci-4 alkyl, -O-C1-4 haloalkyl, or oxo;
  • a twelfth embodiment of the present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R ⁇ is: (1) -OH,
  • Rv is -Ci-4 alkyl or cyclopropyl
  • HetC is a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the ring is attached to the remainder of the compound via a ring carbon atom and a ring N atom is alpha to the ring carbon attached to the remainder of the compound; and wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C1 alkyl, -C1 haloalkyl, -O-C1.4 alkyl, -O-C ⁇ _4 haloalkyl, or oxo;
  • a first class of the present invention includes compounds of Formula (H), or a pharmaceutically acceptable salt thereof:
  • R6' is:
  • Ru is -H or -Cl-4 alkyl
  • R v is -Cl-4 alkyl or cyclopropyl
  • a sub-class of the first class includes compounds of Formula (E), or a pharmaceutically acceptable salt thereof, wherein:
  • Xl ' and X 2 ' are each independently:
  • Ru is -H; and v is methyl, ethyl, or cyclopropyl,
  • a second class of the present invention includes compounds of Formula (ffl), or a pharmaceutically acceptable salt thereof:
  • ⁇ l' and ⁇ 2' are each independently -H or halo
  • R6' is:
  • R v is -C ⁇ _4 alkyl or cyclopropyl.
  • a sub-class of the second class includes compounds of Fomiula (III), or a pharmaceutically acceptable salt thereof, wherein: Xl' and ⁇ 2' are each independently -H, fluoro, chloro, or bromo; and
  • R ⁇ ' is:
  • R v is methyl, ethyl, or cyclopropyl.
  • a thirteenth embodiment of the present invention is a compound of Formula (IN), or a pharmaceutically acceptable salt thereof:
  • Ru is -H or -Ci-6 alkyl
  • Rv is Ci-6 alkyl which is substituted with 1 or 2 substituents each of which is independently: (1) C3-.8 cycloalkyl,
  • each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C ⁇ _6 alkyl, or -O-C ⁇ -6 alkyl;
  • each saturated or mono-unsaturated heterocyclic ring i s (i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C ⁇ .6 alkyl, -C ⁇ _6 haloalkyl, -O-C ⁇ _6 alkyl, -O-C ⁇ -6 haloalkyl, or oxo; and (ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and (D) each heteroaromatic ring or each fused bicyclic heterocycle is
  • Rl is -H or -C ⁇ _6 alkyl
  • a fifteenth embodiment of the present invention is a compound of Formula (IN), or a pharmaceutically acceptable salt thereof, wherein R v is -(CH2)l-4-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently
  • a sixteenth embodiment of the present invention is a compound of Formula (IN), or a pharmaceutically acceptable salt thereof, wherem R v is:
  • ⁇ l and X 2 are each independently
  • R v is 4-fluorobenzyl
  • a seventeenth embodiment of the present invention is a compound of Formula (IN), or a pha ⁇ naceutically acceptable salt thereof, wherein is -H; and all other variables are as first defined in Formula (IN) or as defined in the preceding embodiments or aspects thereof.
  • An eighteenth embodiment of the present invention is a compound of Formula (IN), or a pharmaceutically acceptable salt thereof, wherein R 5 is -H; and all other variables are as first defined in Formula (IN) or as defined in the preceding embodiments or aspects thereof.
  • a nineteenth embodiment of the present invention is a compound of Formula (IN), or a pharmaceutically acceptable salt thereof, wherein R4 is: (1) -H, (2) -C ⁇ -4 alkyl optionally substituted with one of -OH, - ⁇ (RaRb) s or
  • a twentieth embodiment of the present invention is a compound of Formula (IV), or a pharmaceutically acceptable salt thereof, wherein Rk is the same as defined above in the eighth embodiment for compounds of Formula (I); and all other variables are as originally defined in Formula (IN) or as defined in any of the preceding embodiments or aspects thereof.
  • HetA is a 5- or 6-membered heteroaromatic ring containing 1 or 2 ⁇ atoms, wherein HetA is optionally substituted with from I to 3 substituents each of which is independently -C ⁇ 4 alkyl, -C ⁇ _4 haloalkyl, -O-C ⁇ -4 alkyl, -0-C ⁇ 4 haloalkyl, or oxo.
  • HetA is pyrrolyl, pyrazolyl, imidazolyl, pyridyl, or pyrazinyl; which is optionally substituted with from 1 to 3 substituents each of which is independently -C ⁇ alkyl (e.g., methyl), -C ⁇ -4 haloalkyl (e.g., trifluoromethyl) , -O-C ⁇ .4 alkyl (e.g., methoxy), -O-C ⁇ haloalkyl (e.g., -OCF3), or oxo.
  • substituents each of which is independently -C ⁇ alkyl (e.g., methyl), -C ⁇ -4 haloalkyl (e.g., trifluoromethyl) , -O-C ⁇ .4 alkyl (e.g., methoxy), -O-C ⁇ haloalkyl (e.g., -OCF3), or oxo.
  • a twenty first embodiment of the present invention is a compound of Formula (IN), or a pharmaceutically acceptable salt thereof, wherein Rk is the same as defined above in the ninth embodiment for compounds of Formula (I); and all other variables are as originally defined in Formula (IN) or as defined in any of the preceding embodiments or aspects thereof.
  • a twenty-second embodiment of the present invention is a compound of Formula (TV), or a pharmaceutically acceptable salt thereof, wherein R 2 is -H; and all other variables are as originally defined or as defined in the preceding embodiments or aspects thereof.
  • Rl is -Cl-4 alkyl; and all other variables are as originally defined or as defined in the preceding embodiments or aspects thereof, h an aspect of this embodiment, Rl is methyl or ethyl.
  • Still other embodiments of the present invention include compounds of Formula (I) and (TV) respectively, wherein each R a and Rb is independently -H, methyl, or ethyl; each R is independently methyl or ethyl; and all other variables are as originally defined or as defined in any of the foregoing embodiments or aspects thereof.
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention (e.g., a compound of Formula (I) or Formula (H.) or Formula (TIT) or Formula (TV) or any of the specific compounds set forth above) and a pharmaceutically acceptable carrier.
  • a compound of the invention e.g., a compound of Formula (I) or Formula (H.) or Formula (TIT) or Formula (TV) or any of the specific compounds set forth above
  • a pharmaceutically acceptable carrier e.g., a compound of Formula (I) or Formula (H.) or Formula (TIT) or Formula (TV) or any of the specific compounds set forth above
  • a pharmaceutical composition which comprises the product prepared by combining (e.g., mixing) a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
  • composition of (c), wherein the HIV infection/AIDS treatment agent is an antiviral selected from the group consisting of HIN protease inhibitors, non- nucleoside HIN reverse transcriptase inhibitors, and nucleoside HIN reverse transcriptase inhibitors.
  • a combination useful for inhibiting HIN integrase, for treating or preventing infection by HIN, or for preventing, treating or delaying the onset of AIDS which is a therapeutically effective amount of a compound of the invention and a therapeutically effective amount of an HIN infection/AIDS treatment agent selected from the group consisting of HTN/ATDS antiviral agents, immunomodulators, and anti-infective agents.
  • HIN infection/AIDS treatment agent is an antiviral selected from the group consisting of HIV protease inhibitors, non-nucleoside HJN reverse transcriptase inhibitors and nucleoside HIN reverse transcriptase inhibitors.
  • a method of inhibiting HIN integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of the invention.
  • a method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • (m) A method of preventing or treating infection by HIN in a subject in need thereof which comprises administering to the subject the ph rmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • a method of preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject the pharmaceutical composition of (a), (b), (c) or (d) or the combination of (e) or (f).
  • the present invention also includes a compound of the present invention (i) for use in, (ii) for use as a medicament for, or (iii) for use in the preparation of a medicament for: (a) inhibiting HIN protease, (b) preventing or treating infection by HIN, or (c) preventing, treating or delaying the onset of AIDS.
  • the compounds of the present invention can optionally be employed in combination with one or more HTWAIDS treatment agents selected from HIN/AIDS antiviral agents, anti-infective agents, and immunomodulators.
  • Additional embodiments of the invention include the pharmaceutical compositions, combinations and methods set forth in (a)-(n) above and the uses set forth in the preceding paragraph, wherein the compound of the present invention employed therein is a compound of one of the embodiments, or an aspect or feature or sub-feature thereof, described above.
  • C ⁇ _6 alkyl (or “C ⁇ -C6 alkyl”) means a linear or branched chain alkyl group having from 1 to 6 carbon atoms and includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • C ⁇ .4 alkyl means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • the term "Co” as employed in expressions such as "-C ⁇ -6 alkyl- 7 ' means a direct covalent bond. For example, in the group -Cl- alkyl-N(Ra)-Crj-6 alkyl-S(0) n Rk when the second alkylene group is "Co", then the group is -C ⁇ _6 alkyl-N(Ra)-S(0) n Rk.
  • -C ⁇ .6 alkyl- refers to a Cl to C linear or branched alkyl group as just defined which is bivalent. It can alternatively be referred to as "C ⁇ _6 alkylene” or "C ⁇ _6 alkanediyl".
  • a class of alkylenes of particular interest with respect to the invention is -(CH2)l- 6-, and sub-classes of particular interest include -(CH2)l-4 ⁇ , -(CH2)l-3-, -(CH2)i-2-, and -CH2-.
  • C2-6 alkenyl means a linear or branched chain alkenyl group having from 2 to 6 carbon atoms and includes all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyL 3-buteny], isobutenyl, 1-propenyl, 2-propenyl, and ethenyl (or vinyl). Similar terms such as “C2-4 alkenyl” have an analogous meaning.
  • C2-5 alkynyl means a linear or branched chain alkynyl group having from 2 to 5 carbon atoms and includes all of the pentynyl isomers as well as 1-butynyl, 2-butynyl, 3-butynyl, 1-propynyl, 2- ⁇ ropynyl, and ethynyl (or acetylenyl). Similar terms such as “C2-4 alkynyl” have an analogous meaning.
  • C3_s cycloalkyl (or “C3-C8 cycloalkyl”) means a cyclic ring of an alkane having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl). Similar terms such as “C3..6 cycloalkyl” have an analogous meaning.
  • halogen refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
  • C ⁇ -6 haloalkyl (which may alternatively be referred to as “C ⁇ -C6 haloalkyl” or “halogenated C ⁇ -C6 alkyl”) means a Ci to C6 linear or branched alkyl group as defined above with one or more halogen substituents.
  • C ⁇ -4 haloalkyl has an analogous meaning.
  • C ⁇ -6 fluoroalkyl has an analogous meaning except that the halogen substituents are restricted to fluoro.
  • a class of fluoroalkyls of particular interest with respect to the invention is the series (CH2) ⁇ -4CF (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
  • An oxo substituent on a carbon atom in a heteroaromatic ring refers to the keto form of the keto-enol tautomer, as exemplified here for an ox ⁇ pyridinyl substituent:
  • aryl refers to an aromatic carbocychc ring or an aromatic carbocychc fused ring system.
  • the fused ring system contains two or more carbocyclic rings hi which each ring shares two adjacent carbon atoms with at least one other ring.
  • the aryl group may be attached to the rest of the molecule at any carbon atom which results in a stable compound.
  • a subset of aryl groups particularly suitable for use in the present invention includes those selected from phenyl, naphthyl, anthryl, and phenanthryl. Another particularly suitable subset of aryl groups is phenyl and naphthyl. Still another particularly suitable subset of aryl groups is phenyl per se.
  • heterocyclic ring refers to a 4- to 8-membered, saturated or unsaturated monocyclic ring that contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, from 1 to 5 heteroatoms, from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom) independently selected from N, O and S and a balance of carbon atoms (the ring typically contains at least one carbon atom); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quatemized.
  • heteroatoms e.g., from 1 to 6 heteroatoms, from 1 to 5 heteroatoms, from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom
  • heteroatoms e.g., from 1 to 6 heteroatoms, from 1 to 5 heteroatoms, from 1 to 4 heteroatoms, from 1 to 3 heteroatoms,
  • the heterocyclic ring may be attached to the rest of the molecule via any heteroatom or carbon atom in the ring, provided that attachment results in the creation of a stable structure. WThen the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • a subset of the heterocyclic rings useful in the present invention includes any 4- to 7-membered saturated or mono-unsaturated heterocyclic ring, wherein the ring contains at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S.
  • a subgroup of this subset includes any 4- to 7-membered saturated or mono-unsaturated heterocyclic ring in which the ring contains at least one carbon atom and a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms.
  • saturated heterocyclic rings include piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidi ⁇ yl, oxazolidiny], is ⁇ oxazolidinyl, pyirolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl,
  • thiadiazepanyl dithiazepanyl, azepanyl (i.e., N- 7 ), diazepanyl, thiadiazinanyl (e.g., 1,2,6-
  • thiadiazinanyl s " N J , and dioxanyl Representative examples of mono-unsaturated rings are the same as the saturated rings listed in the preceding sentence except that each ring contains a double bond.
  • heterocycHc rings useful in the present invention includes any 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S.
  • a useful subgroup of this subset includes any 5- or 6-membered saturated or mono-unsaturated heterocyclic ring in which the ring contains at least one carbon atom and a total of from 1 to 4 heteroatoms independentiy selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms.
  • Another useful subgroup is identical to the preceding subgroup, except that it is limited to saturated heterocyclic rings.
  • Still another subgroup of this subset of heterocyclic rings suitable for use in the present invention includes any 5- or 6-membered saturated ring containing 1 or 2 N atoms and carbon atoms.
  • Representative examples of this subgroup include piperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, piperidinyl, andhexahydropyrimidinyl.
  • heterocyclic rings useful in the present invention are the heteroaromatic rings.
  • heteroaromatic ring (alternatively “heteroaryl ring”) generally refers to a heterocyclic ring as defined above in which the ring is an aromatic ring.
  • a useful subgroup of this subset includes any 5- or 6- rnembered monocyelic aromatic ring which consist of carbon atoms and from 1 to 4 heteroatoms independently selected from N, O and S,
  • Representative examples of this subgroup include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, tiiazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • Another useful subgroup of this subset includes any 5- or 6-membered heteroaromatic ring in which the ring contains a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms.
  • Another useful subgroup includes any 5- or 6-membered heteroaromatic ring containing 1 or 2 N atoms and carbon atoms.
  • fused bicyclic hetcrocycle refers to any 8- to 12-membered bicyclic ring system containing one or more heteroatoms (e.g., from 1 to 6 heteroatoms, from 1 to 5 heteroatoms, from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom) independently selected from N, O and S, in which one ring contains all of the heteroatoms or each ring contains at least one of the heteroatoms, and wherein each ring is saturated or unsaturated, and two adjacent ring atoms are shared by each of the rings in the ring system and each of the two shared atoms is independently a carbon atom or a heteroatom.
  • heteroatoms e.g., from 1 to 6 heteroatoms, from 1 to 5 heteroatoms, from 1 to 4 heteroatoms, from 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom
  • any one or more of the nitrogen and sulfur heteroatoms in the ring system is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized.
  • the fused bicyclic heterocycle may be attached to the rest of the molecule via any heteroatom or carbon atom in the ring, provided that attachment results in the creation of a stable structure.
  • the bicyclic heterocycle has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • a subset of the fused bicyclic heterocycles useful in the present invention includes any 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic.
  • bicyclic heterocycles in this subset include bcnzotria-joiyl, indolyl, isoindolyl, indazolyl, indolinyl, isomdolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetraliydroisoquinolinyl,
  • an "unsaturated" ring is a partially or fully unsaturated ring.
  • heterocyclic ring described as containing from “1 to 4 heteroatoms” means the ring can contain 1, 2, 3 or 4 heteroatoms.
  • any variable e.g., Ra, Rb 5 o Rc
  • its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • substituted e.g., as in "each aryl is optionally substituted with from 1 to 5 substituents "
  • substituted includes mono- and poly-substitution by a named substituent to the extent such single and multiple substitution (including multiple substitution at the same site) is chemically allowed.
  • the symbol " ' w ⁇ " in front of an open bond in the structural formula of a group marks the point of attachment of the group to the rest of the molecule.
  • the compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as mixtures of stereoisomers or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.
  • a reference herein to a compound of Formula (I) is a reference to compound I per se, or to any one of its tautomers per se (e.g., IA or IB), or to mixtures of two or more of the tautomers (e.g., two or more of I, IA, and IB).
  • the compounds of the present invention are useful in the inhibition of HTV integrase, the prevention or treatment of infection by human immunodeficiency virus (HIN) and the prevention, treatment or the delay in the onset of consequent pathological conditions such as AIDS.
  • Preventing AIDS, treating AIDS, delaying the onset of AIDS, or preventing or treating infection by HIN is defined as including, but not limited to, treatment of a wide range of states of HTV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIN.
  • the compounds of this invention are useful in treating infection by HIN after suspected past exposure to HIN by such means as blood transfusion, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in estabhshing or determining the binding site of other antivirals to HIN integrase, e.g., by competitive inhibition.
  • the compounds of the present invention can be administered in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to a salt which possesses the effectiveness of the parent compound and which is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
  • Suitable salts include acid addition salts which may, for example, be formed by mixing a solution of the compound of the present invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • suitable pharmaceutically acceptable salts thereof can include alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
  • alkali metal salts e.g., sodium or potassium salts
  • alkaline earth metal salts e.g., calcium or magnesium salts
  • suitable organic ligands such as quaternary ammonium salts.
  • pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
  • the compounds of the present invention can be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques), by inhalation spray, or rectally, in the form of a unit dosage of a pharmaceutical composition containing a therapeutically effective amount of the compound and conventional non-toxic pharmaceuticaily-acceptable carriers, adjuvants and vehicles.
  • administration and variants thereof (e.g., " administering" a compound) in reference to a compound of the invention mean providing the compound to the individual in need of treatment.
  • active agents e.g., antiviral agents useful for treating HIN infection or AIDS
  • “administration” and its variants are each understood to include concurrent and sequential provision of the compound and other agents.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combining the specified ingredients in the specified amounts.
  • pharmaceutically acceptable is meant that the ingredients of the pharmaceutical composition must be compatible with each other and not deleterious to the recipient thereof.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a t i ssue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which mcludes alleviation of the symptoms of the disease being treated
  • active compound i.e., active ingredient
  • references to the amount of active ingredient are to the free acid or free base form of the compound.
  • compositions can be in the form of orally-admimstrable suspensions or tablets or capsules, nasal sprays, sterile i ⁇ jectible preparations, for example, as sterile mjectible aqueous or oleagenous suspensions or suppositories.
  • sterile i ⁇ jectible preparations for example, as sterile mjectible aqueous or oleagenous suspensions or suppositories.
  • Suitable methods and ingredients are described in Remington's Pharmaceutical Sciences. 18 th edition, edited by A R. Gennaro, Mack Publishing Co., 1990, which is herein incorporated by reference in its entirety.
  • the compounds of this invention can be administered orally in a dosage range of 0.001 to 1000 mg/kg of mammal (e.g., human) body weight per day in a single dose or in divided doses.
  • mammal e.g., human
  • One preferred dosage range is 0.01 to 500 mg/kg body weight per day orally in a single dose or in divided doses.
  • Another preferred dosage range is 0.1 to 100 mg/kg body weight per day orally in single or divided doses.
  • the compositions can be provided in the form of tablets or capsules containing 1.0 to 500 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, and 500 milhgrams of t he active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the specific dose level and frequency of dosage for any particular patient may be va ⁇ ed and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
  • the present invention is also directed to use of the HTV integrase inhibitor compounds of the present invention with one or more agents useful in the treatment of HTV infection or AIDS.
  • the compounds of this invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of one or more of the HIN/AIDS antivirals, imunomodulators, antiinfectives, or vaccines useful for treating HTV infection or AIDS.
  • Suitable antiviral agents include those listed in the following Table. D ⁇ U ⁇ Name Manufacturer Indication (Activity.
  • abacavir Glaxo Welcome HIN infection, AIDS, ARC GW 1592 (ZIAGEN®) (nRTI) 1592U89 abacavir + lamivudi ⁇ e + GlaxoSmithKIine HTV infection, AIDS, ARC zidovudine (TRIZrVIR®) (nRTIs) acemannan Carrington Labs ARC (Irving, TX)
  • CXCR4 antagonist amprenavir GlaxoSmithKIine HIN infection, AIDS, 141 W94 (AGENERASE®) ARC (PI) G 141 VX478 (Vertex) ansamycin Adria Laboratories ARC LM 427 (Dublin, OH)
  • nRTI didanosine, (VTDEX®) combination with AZT/d4T dideoxyinosine
  • DPC 681 & DPC 684 DuPont HTV infection, AIDS, ARC (Pis)
  • ARC lamivudine + zidovudine GlaxoSmithKIine HTV infection, AIDS, (COMBINIR®) ARC (nRTI) lobucavir Bristol-Myers Squibb CMN infection lopinavir (ABT-3 S) Abbott HIN infection, AIDS, ARC (PI)
  • Iopinavir + ritonavir Abbott (KALETR A®) HTV infection, AIDS, ARC (ABT-378/r) (PD mozenavir AVID (Camdcn, ⁇ J) HTV infection, ADDS, ARC (DMP-450) (PI) nelfinavir Agouron HTV infection, AIDS, (VIRACEPT®) ARC (PI) nevirapine Boeheringer HIN infection, AIDS,
  • PRO 140 Progenies HIN infection, AIDS, ARC (CCR5 co-receptor inhibitor)
  • PRO 542 Progenies HIN infection, AIDS, ARC (attachment inhibitor) trisodium Astra Pharm. Products, CMN retinitis, HIN infection, phosphonofo ⁇ nate Inc other CMN infections
  • TAK-779 Takeda HIV infection, AIDS, ARC
  • VREAD® injectable CCR5 receptor antagonist
  • ARC nucleotide reverse transcriptase inhibitor
  • Boehringer Ingelheim HIN infection AIDS, ARC (PI)
  • TMC-126 Tibotec HIN infection, AIDS, ARC PD valaciciovir GlaxoSmithKIine genital HSN & CMN infections virazole Viratek ICN (Costa asymptomatic HIV positive, ribavirin Mesa, CA) LAS, ARC zidovudi ⁇ e; AZT GlaxoSmithKIine HIN infection, AIDS, ARC, (RETROVTR®) Kaposi's sarcoma in combination with other therapies (nRTD
  • PI protease inhibitor
  • nnRTI non-nucleoside reverse transcriptase inhibitor
  • a compound of the present invention can also be administered in combination with an HIV integrase inhibitor such as a compound described in WO 99/625l3,WO 99/62520, or WO 99/62897.
  • a compound of the present invention can also be adtrjinistered in combination with a CCR5 receptor antagonist, such as a compound described in WO 99/04794, WO 99/09984, WO 99/38514, WO 00/59497, WO 00/59498, WO 00/59502, WO 00/59503, WO 00/76511, WO 00/76512, WO 00/76513, WO 00/76514 , WO 00/76792, or WO 00/76793.
  • the compounds of this invention may be effectively adr nosticered, whether at periods of pre- exposure and/or post-exposure, in combination with effective amounts of one or more HIV/AIDS antivirals, immunomodulators, antiinfectives, ⁇ r vaccines useful for treating HTV infection or AIDS disclosed in the Table in WO 02/30930, which is herein incorporated by reference in its entirety.
  • HJN/AIDS antivirals and other agents wi II typically be employed in these combinations in their conventional dosage ranges and regimens as reported in the art, including the dosages described in the Physicians' Desk Reference, 54 & edition, Medical Irteonornics Company, 2000.
  • the dosage ranges for a compound of the invention in these combinations are the same as those set forth above.
  • AIDS acquired nmunodeficiency syndrome
  • DMSO dimethyl sulfoxide
  • ES-MS eletron spray mass spectroscopy
  • HIV human immunodeficiency virus
  • NaHMDS sodium hexamethyldisilazide
  • the compounds of the present invention can be readily prepared according to the following reaction schemes and examples, or modifications thereof, using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. Unless otherwise indicated, all variables are as defined above.
  • the carboxylate 1-6 can be hydrolyzed to give the 7-carboxylic acid 1-7.
  • Carboxylate 1-6 can also be treated with amine to give the 7-carbo ⁇ amide 1-8.
  • the piperazin-2-one 1-3 reactant can be obtained by alkylation of amine-protected piperazin-2-one 1-1 followed by deprotection to afford 1-3, as depicted in Scheme 1.
  • Compound 1-1 can be prepared using methods described in Choi et al., /. Med. Chem. 1999, 3647; Najman- Bro ⁇ zewska et al., Pharmazie 1997, 198; Fryer et al., /. Org. Chem. 1991, 3715, Dinsmore et al, Organic Prep.
  • dialkylalkoxymethylenemalonates 1-4 are commercially available (e.g., diethylethoxymethylenemalonate or dimethylmethoxy-methylenemalonate). Others can be obtained by preparative methods known in the art; e.g., heterocyclylalkyloxymethylcne malonates can be prepared by the method described in Boger et al., J. Org. Chem 1988, 3408, or routine variations thereof.
  • the protection and deprotection of the amine in the piperazin-2-one can be accomplished using conventional amine protecting groups, such as those described in Protective Groups in Organi Chemistry, ed, J.F.W. McOmie, Plenum Press, 1973 and in T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sous, 1991.
  • Scheme 2 exemplifies the same approach as set forth in Scheme 1 for the preparation of compounds embraced by Formula (II).
  • 4-((aryl- or alkyl- oxy)carbonyl)piperazin-2-one 2-1 is alkylated with benzyl bromide 2-2 in the presence of a base (e.g., LiHMDS, NaHMDS, or NaH) to afford l-benzyI-4-((aryl- or alkyl-oxy)carbonyl)piperazm- 2-one 2-3, which can be deprotected by standard methods (e.g., treatment with hydrogen) to afford l-benzylpiperazin-2-one 2-4.
  • a base e.g., LiHMDS, NaHMDS, or NaH
  • elevated temperature e.g., from about 60 to about 90°C
  • 2,2-dialkyloxycarbonylethenyl-substituted product 2-6 can then be treated with a deprotonatmg agent (e.g., LiHMDS) in an aprotic solvent (e.g., DMF) to provide the alkyl 2- benzyl-8-hydroxy-l-oxo-l,2,3 s 4-tetrahydropy ⁇ olopyrazme-7-carboxylate 2-7.
  • Carboxylate 2-7 can be converted to the corresponding acid 2-8 by hydrolysis (e.g., with NaOH) and to the corresponding amide by treatment with an amine in the presence of a Lewis base (e.g., AlC-3).
  • Scheme 3 illustrates a method for preparing compounds of Formula (IN).
  • the piperazin-2-o ⁇ e 4-2 can be obtained by treatment of amine-protected pi ⁇ erazin-2-one 4-1 with base (e.g., DHMDS, NaHMDS, or NaH) in DMF, followed by addition of methoxymethyl chloride or similar aroide protecting group. Selective deprotection of the amine protecting group by hydrogenolysis provides pi ⁇ erazin-2-one 4-3.
  • base e.g., DHMDS, NaHMDS, or NaH
  • Step 1 Benzyl 4-benzyl-3-oxopi ⁇ erazine-I-carboxylate
  • Step 3 E yl 2-benzyl-8-hy ⁇ roxy-l-oxo-l,2,3,4-tet ⁇ r ⁇ ydro ⁇ yrt ⁇ lo[l,2-fl]-pyrazine-7- carboxylate
  • the title compound was prepared using a procedure similar to that described in Example 2, except that ethyl 2-ber ⁇ zyl-8-hydroxy-l-oxo-l 7 2,3,4-tetrahydro ⁇ yrrolo-[l,2- ⁇ ] ⁇ yrazine-7-carboxylate was substituted with ethyl 2-(4-fluorobenzyl)-8-hydroxy-l-oxo-l,2,3,4- terrahydropyrrolo[l,2- ⁇ ]pyrazi ⁇ e-7-carboxylate.
  • the title compound was prepared using a procedure similar to that described in Example 5, except that methylamine was substituted with ethylamjne.
  • Step l l-(3-chlorobenzyI) ⁇ iperazin-2-one
  • Step 2 Ethyl 2-(3-chlorobenzyl)-8-hydroxy-l-oxo-l,2,3,4-tetral ⁇ ydro ⁇ yrrolo[l,2- ⁇ ]- pyrazine-7-carboxylate
  • Example 2 except that ethyl 2-benzyl-8-hydroxy-l-oxo-l,2,3,4-tetrahydropyrrolo-[l,2- a]pyrazine-7-carboxylate was substituted with ethyl 2-(3-chlorobenzyI)-8-hydroxy-l-oxo-l, 2,3,4- tetrahydropyrrolo[I,2-- ⁇ ]pvrazine-7-carboxylate.
  • Step 1 l-Methyl ⁇ iperazin-2-one
  • Step 2 Ethyl S-hydroxy-2-methyl-l-oxo ,2,3,4-tetrahydiOpyrroIo[l,2- ⁇ ]pyrazine-7- carboxyl te
  • the title compound was prepared using a procedure similar to that described in Example 1 (Step 3), except that l-benzylpiperazin-2-one was substituted with l-methylpiperazin- 2-one.
  • Step_3 N"(4-Fluorobenzyl)-8-hydroxy-2-methyl-l-oxo-l,2,3,4-tetrahydro-pyrrolo[l,2- fl]pyrazine-7-cafboxamide
  • the title compound was prepared using a procedure similar to that described in Example 5, except that methylamine was substituted with 4-fluorob ⁇ nyl-amine.
  • Step 1 f ⁇ rt-Butyl 4-(4-chlorobenzyl)-3-oxopiperazine-l -carboxylate
  • the title compound was prepared using a procedure similar to that described in Example 13, except that 4-chlorobenzyl bromide (Step 1) was substituted with 3-chloro-4- fJuorobenzyl bromide.
  • Example 5 except that ethyl 2-(4-fluorobenzyI)-8-hydroxy-l-oxo-l,2,3 ] 4-ietrahy ⁇ ropyrrolo[l,2- ⁇ ]pyrazine-7-carboxylate was subsituted with ethyl 2-(4-chlorobenzyl)-8-hydroxy-l-oxo-l,2,3,4- tetrahydropyrrolo[l,2- ⁇ 7] ⁇ yrazine-7-carboxylate (Example 13).
  • Example 12 The title compound was prepared using a procedure similar to that described in Example 5, except that ethyl 2-(4'fluorobenzyl)-8-hydroxy-l-oxo-l,2,3,4-tetrahydropyrTolo[l,2- ⁇ ]pyrazine-7-carboxylate was subsituted with ethyl 2-(3,4-difluorobenzyl)-8-hydroxy-l-oxo- l,2,3,4-tetiahydro ⁇ yrrolo[l,2- ⁇ ]pyrazine-7-carboxylate (Example 12).
  • an oral composition of a compound of this invention 50 mg of compound of Example 1 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0 hard gelatin capsule.
  • Encapsulated oral compositions containing any one of the compounds of Examples 2-18 can be similarly prepared.
  • EXAMPLE 20 HEN Integrase Assay: Strand Transfer Catalyzed by Recombinant Integrase Assays for the strand transfer activity of integrase were conducted in accordance with WO 02/30930 for recombinant integrase. Representative compounds of the present invention exhibit inhibition of strand transfer activity in this assay. For example, the compounds prepared in Examples 1-18 were tested in the integrase assay and all were found to have IC50's less than 1.5 micromolar- In particular, the compounds prepared in Examples 1-10 were all found to have ICso's less than 0.7 micromolar in the integrase assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de 8-hydroxy-1-oxo-tétrahydropyrrolopyrazine qui constituent des inhibiteurs de l'intégrase VIH et des inhibiteurs de la réplication du VIH. Lesdits composés sont représentés par la formule (I), dans laquelle Rl, R2, R3, R4, R5 et R6 ont la signification indiquée dans la description. Lesdits composés sont utiles pour prévenir et traiter l'infection par le VIH et pour prévenir le sida, retarder son apparition et le traiter. Lesdits composés sont employés contre l'infection par le VIH et le sida, soit tels quels soit sous la forme de leurs sels acceptables pharmaceutiquement. Lesdits composés et leurs sels peuvent être employés en tant que principe actif dans des compositions pharmaceutiques, éventuellement en association avec d'autres antiviraux, immunomodulateurs, antibiotiques ou vaccins. L'invention concerne également des méthodes pour prévenir ou traiter le sida, ou retarder son apparition, ainsi que des méthodes pour prévenir et traiter l'infection par le VIH.
PCT/US2003/028363 2002-09-11 2003-09-10 Composes de 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine utilises comme inhibiteurs de l'integrase du vih WO2004047725A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/526,280 US7399763B2 (en) 2002-09-11 2003-09-10 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors
JP2004555293A JP2005538184A (ja) 2002-09-11 2003-09-10 Ｈｉｖインテグラーゼ阻害剤として有用な８−ヒドロキシ−１−オキソ−テトラヒドロピロロピラジン化合物
CA002498566A CA2498566A1 (fr) 2002-09-11 2003-09-10 Composes de 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine utilises comme inhibiteurs de l'integrase du vih
DE60322919T DE60322919D1 (de) 2002-09-11 2003-09-10 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen
EP03812013A EP1539714B1 (fr) 2002-09-11 2003-09-10 Composes de 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine utilises comme inhibiteurs de l'integrase du vih
AU2003302382A AU2003302382B2 (en) 2002-09-11 2003-09-10 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40974502P 2002-09-11 2002-09-11
US60/409,745 2002-09-11

Publications (2)

Publication Number Publication Date
WO2004047725A2 true WO2004047725A2 (fr) 2004-06-10
WO2004047725A3 WO2004047725A3 (fr) 2004-09-30

Family

ID=32393259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028363 WO2004047725A2 (fr) 2002-09-11 2003-09-10 Composes de 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine utilises comme inhibiteurs de l'integrase du vih

Country Status (7)

Country Link
US (1) US7399763B2 (fr)
EP (1) EP1539714B1 (fr)
JP (1) JP2005538184A (fr)
AT (1) ATE404563T1 (fr)
CA (1) CA2498566A1 (fr)
DE (1) DE60322919D1 (fr)
WO (1) WO2004047725A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1677599A1 (fr) * 2003-10-20 2006-07-12 Merck & Co., Inc. Composes pyridopyrrolopyrazine dione hydroxy utiles comme inhibiteurs de l'integrase du vih
WO2007050510A2 (fr) * 2005-10-27 2007-05-03 Merck & Co., Inc. Inhibiteurs de l'integrase du vih
US7476666B2 (en) 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
WO2010031816A1 (fr) 2008-09-19 2010-03-25 Nerviano Medical Sciences S.R.L. Dérivés de 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazine-1-one
WO2018005865A1 (fr) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthèse de n-(hétéroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
US10065950B2 (en) 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
US10981922B2 (en) 2012-04-26 2021-04-20 Francis Xavier Tavares Synthesis of lactams
US11708337B2 (en) 2018-08-24 2023-07-25 G1 Therapeutics, Inc. Synthesis of 1,4-diazaspiro[5.5]undecan-3-one

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003267098B2 (en) * 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
CN1964975B (zh) * 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
CA2610029A1 (fr) * 2005-06-01 2006-12-07 Bioalliance Pharma Combinaisons synergiques comprenant un compose de styrylquinoleine et d'autres agents therapeutiques contre une infection au vih

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
AU4719699A (en) * 1998-06-26 2000-01-17 Du Pont Pharmaceuticals Company Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
WO2002036734A2 (fr) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza- et polyaza-naphtalenyl cetones utiles en tant qu'inhibiteurs de l'integrase du vih
EA200300449A1 (ru) 2000-10-12 2003-10-30 Мерк Энд Ко., Инк. Аза- и полиаза-нафталинилкарбоксамиды, полезные в качестве ингибиторов вич-интегразы
AU2002215328B2 (en) * 2000-10-12 2005-11-17 Merck Sharp & Dohme Corp. Aza- and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
EP1326610B1 (fr) * 2000-10-12 2006-11-15 Merck & Co., Inc. Aza- et polyaza-naphthalenyl carboxamides convenant comme inhibiteurs de l'integrase du vih
EP1441735B1 (fr) 2001-10-26 2006-02-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibiteurs de l'integrase du vih a base d'hydroxypyrimidinone carboxamide n-substitue
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
AU2003267098B2 (en) * 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821241A (en) * 1994-02-22 1998-10-13 Merck & Co., Inc. Fibrinogen receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1539714A2 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1677599A1 (fr) * 2003-10-20 2006-07-12 Merck & Co., Inc. Composes pyridopyrrolopyrazine dione hydroxy utiles comme inhibiteurs de l'integrase du vih
EP1677599A4 (fr) * 2003-10-20 2008-10-22 Merck & Co Inc Composes pyridopyrrolopyrazine dione hydroxy utiles comme inhibiteurs de l'integrase du vih
US7476666B2 (en) 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
WO2007050510A2 (fr) * 2005-10-27 2007-05-03 Merck & Co., Inc. Inhibiteurs de l'integrase du vih
WO2007050510A3 (fr) * 2005-10-27 2007-10-04 Merck & Co Inc Inhibiteurs de l'integrase du vih
US8394802B2 (en) 2008-09-19 2013-03-12 Nerviano Medical Sciences S.R.L. 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
WO2010031816A1 (fr) 2008-09-19 2010-03-25 Nerviano Medical Sciences S.R.L. Dérivés de 3,4-dihydro-2h-pyrrolo[1,2-a]pyrazine-1-one
US8981092B2 (en) 2008-09-19 2015-03-17 Nerviano Medical Sciences S.R.L. Substituted 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-ones as modulators of protein kinase activity
US10065950B2 (en) 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
US10981922B2 (en) 2012-04-26 2021-04-20 Francis Xavier Tavares Synthesis of lactams
WO2018005865A1 (fr) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthèse de n-(hétéroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
US10865210B2 (en) 2016-07-01 2020-12-15 G1 Therapeutics, Inc. Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
US11629150B2 (en) 2016-07-01 2023-04-18 G1 Therapeutics, Inc. Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
US11708337B2 (en) 2018-08-24 2023-07-25 G1 Therapeutics, Inc. Synthesis of 1,4-diazaspiro[5.5]undecan-3-one
US12264135B2 (en) 2018-08-24 2025-04-01 Pharmacosmos Holding A/S Synthesis of 1,4-diazaspiro[5.5]undecan-3-one

Also Published As

Publication number Publication date
JP2005538184A (ja) 2005-12-15
WO2004047725A3 (fr) 2004-09-30
DE60322919D1 (de) 2008-09-25
EP1539714A4 (fr) 2007-04-25
ATE404563T1 (de) 2008-08-15
US20050288293A1 (en) 2005-12-29
EP1539714A2 (fr) 2005-06-15
US7399763B2 (en) 2008-07-15
CA2498566A1 (fr) 2004-06-10
EP1539714B1 (fr) 2008-08-13
AU2003302382A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
CA2472372C (fr) Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
AU2003267098B2 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
EP1326610B1 (fr) Aza- et polyaza-naphthalenyl carboxamides convenant comme inhibiteurs de l'integrase du vih
EP1441735A1 (fr) Inhibiteurs de l'integrase du vih a base d'hydroxypyrimidinone carboxamide n-substitue
AU2003216049A1 (en) Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
EP1326611A1 (fr) Azanaphthalenylcarboxamides et polyazanaphthalenylcarboxamides utiles en tant qu'inhibiteurs de la vih integrase
AU2002215328A1 (en) AZA- and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
EP1496836B1 (fr) N-(benzyl substitue)-8-hydroxy-1,6-naphthyridine-7- carboxamides utiles en tant qu'inhibiteurs d'integrase de hiv
KR20170045308A (ko) 인간 면역결핍 바이러스 복제의 억제제로서 이미다조[1,2-a]피리딘 유도체
WO2004047725A2 (fr) Composes de 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine utilises comme inhibiteurs de l'integrase du vih
US20120220571A1 (en) Hiv integrase inhibitors
AU2003302382B2 (en) 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors
CA2542047A1 (fr) Composes pyridopyrrolopyrazine dione hydroxy utiles comme inhibiteurs de l'integrase du vih
KR20180025928A (ko) 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
AU2002334207B8 (en) N-substituted hydroxpyrimidinone carboxamide inhibitors of HIV integrase
WO2004080402A2 (fr) Sel de potassium d'un inhibiteur de hiv integrase
AU2002334207A1 (en) N-substituted hydroxpyrimidinone carboxamide inhibitors of HIV integrase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003302382

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10526280

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2498566

Country of ref document: CA

Ref document number: 2004555293

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003812013

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003812013

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载